Arrhythmias & electrophysiology
Catheter ablation to prevent malignant ventricular arrhythmias in symptomatic Brugada syndrome: A systematic review and meta-analysis
Pooled resultResult — go to the resultRelative risk 0.22 95% CI 0.05–0.99Authors' conclusion
These findings support CA to prevent recurrence of VA in patients with symptomatic BrS on top of standard therapy, with high procedural success rates and an acceptable safety profile.
Study context
- Population
- Patients with high-risk symptomatic Brugada syndrome
- Participants
- 584 patients5 studies
- Comparison
- Catheter ablation (CA) vs standard therapy
- CAn = 331
- Standard therapyn = 253reference
- Outcome
- Recurrence of malignant VA or appropriate ICD therapy
- Follow-up
- During
Methodological detailsrandom-effects
- Random-effects
Pooled result
As reported in the abstract
Relative risk
0.22
95% CI 0.05–0.99
P = 0.049
CAvs Standard therapy
RR 0.22 (95% CI 0.05–0.99); P = 0.049
Further pooled results
- Procedural success with CA
- 98.1% (95% CI 83.9-100.0) · ECG normalization after Ajmaline challenge · Elimination of abnormal electrograms 100% (95% CI 99.6-100.0) · Noninducibility 94.9%
Primary endpoint, time-to-event analysis
- Time-to-event analysis confirmed robustness of findings: HR 0.17 (95% CI 0.04-0.73)
- P = 0.017
Safety
- Complications — CA
- 2.4% (95% CI 0.0–9.0)
Original publication
Catheter ablation to prevent malignant ventricular arrhythmias in symptomatic Brugada syndrome: A systematic review and meta-analysis. Heart Rhythm. Published 26 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →